Novartis says Glivec misses main goal in study
(Reuters)
Reuters - Novartis AG's cancer drug Glivec failed
to meet its main target in a late-stage study of patients with
chronic myeloid leukaemia (CML), the Swiss drugmaker said on
Friday.
http://us.rd.yahoo.com/dailynews/rss/health/*http://news.yahoo.com/s/nm/20080613/hl_nm/novartis_dc